novocure(NVCR) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Novocure Reports Third Quarter 2024 Financial Results Quarterly net revenues of $155 million, up 22% year-over-year, with 4,113 active patients on therapy as of September 30, 2024 FDA approves Optune Lua for the treatment of metastatic non-small cell lung cancer ® After 22 years as CEO, Asaf Danziger announces planned retirement at year end, will be succeeded by current CFO Ashley Cordova Christoph Brackmann appointed Chief Financial Officer, effective January 1, 2025 Root, Switzerland – Novocu ...